How to NEVER Have a Heart Attack with Cardiologist Brett Nowlan, MD Pt. 2 – Diet Details & Meds

Heart attack prevention is framed around detecting coronary plaque and treating risk based on that biology. The clinician argues that cholesterol numbers are not equally meaningful when plaque is absent versus clearly present. Once plaque exists, the conversation shifts toward proven risk reduction tools rather than lifestyle advice alone. LDL lowering is emphasized as the most important modifiable lever when plaque threatens future events. Medication choices are discussed with a patient-centered tone, balancing benefit, tolerability, and consistent follow-up monitoring. Heart attack and stroke risk are presented as cumulative outcomes shaped by many years of exposure and behavior. A practical approach is to define the goal, document baseline plaque status, and track progress with repeat objective markers.

Medication strategy includes statins as foundational therapy for many patients with documented plaque and elevated risk. Ezetimibe is described as an effective add-on that can drive LDL lower when statins do not reach the desired target. Repatha is discussed as a highly potent option reserved for very high-risk profiles or difficult-to-control LDL patterns. Blood pressure control is treated as equally important, because hypertension multiplies vascular damage even with good cholesterol. ARBs are mentioned as one blood-pressure class that can fit well when metabolic risk factors also need attention. The clinician stresses that dosing and monitoring reduce side effects while preserving the protective benefit of therapy. Medication is portrayed as responsible prevention when matched to plaque burden, not as a shortcut for avoiding lifestyle work.

Diet details focus on matching carbohydrate intake to metabolic health rather than enforcing a single universal eating plan. Triglycerides, HDL patterns, fasting glucose, and inflammatory markers are used to infer insulin resistance and dietary tolerance. Metabolic syndrome is described as a warning pattern that often predicts faster plaque progression and higher event risk. Vascepa is discussed in relation to triglyceride management and cardiometabolic risk in appropriate higher-risk situations. Omega-3 and fish oil are mentioned with realistic expectations, emphasizing that effects are modest without foundational habits. The clinician repeatedly returns to sleep, movement, and weight management as levers that improve blood pressure and lipids together. The closing theme is consistency: measure the right risks, treat plaque aggressively when needed, and keep follow-up disciplined.